Boehringer Ingelheim Humira biosimilar available at low wholesale acquisition cost

Key takeaways:

• Adalimumab-adbm injection – a Humira biosimilar – is to be priced at 81% discount to Humira.
• Under the brand name Cyltezo, the biosimilar is priced at a 5% discount to Humira.

Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.

Adalimumab-adbm, Boehringer Ingelheim’s interchangeable biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory diseases, is set to be priced at an 81% discount to Humira.

The biosimilar is also available under the brand name Cyltezo. Launched in July, Cyltezo is priced at a 5% discount to Humira.

“We understand that finding affordable medications is a persistent challenge for many, which is why we strive to ensure our products are widely accessible,” Stephen Pagnotta, executive director and biosimilar commercial lead at Boehringer Ingelheim, said in the release. “Biosimilars are intended to contribute to the economic sustainability of health care systems, and it is our hope that this dual pricing approach will contribute to that sustainability, improve access to Adalimumab-adbm and help meet the varied needs of people with a variety of chronic inflammatory diseases.”

The citrate-free formulation is available as 40 mg/0.8 mL, 20 mg/0.4mL and 10 mg/0.2mL pre-filled syringes, as well as a 40 mg/0.8 mL autoinjector.